Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Amgen Raises FY2025 GAAP EPS Guidance from $10.97-$12.11 to $13.76-$14.60 vs $11.36 Est

Author: Benzinga Newsdesk | November 04, 2025 04:03pm

Amgen Inc.

Reconciliation of GAAP EPS Guidance to Non-GAAP 

EPS Guidance for the Year Ending December 31, 2025

(Unaudited)



 

 

 

 

 

 

 
GAAP diluted EPS guidance

 		$ 13.76

 		—

 		$ 14.60
Known adjustments to arrive at non-GAAP*:

 

 

 

 

 

 
Acquisition-related expenses (a)

 		8.70

 		—

 		8.74
Impairment of intangible assets (b)

 

 

 		1.94

 

 
Net gains from equity investments

 

 

 		(3.86)

 

 
Other

 

 

 		0.02

 

 
Non-GAAP diluted EPS guidance

 		$ 20.60

 		—

 		$ 21.40

Posted In: AMGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist